Cubist Systematic Strategies’s Unity Biotechnology UBX Stock Holding History

Cubist Systematic Strategies’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,156	Closed	-$7K	–	4735
2022 Q2	$7K	Sell	1,156 -3,329	-74%	-$27.8K	﹤0.01%	4287
2022 Q1	$50K	Sell	4,485 -3,292	-42%	-$36.9K	﹤0.01%	3379
2021 Q4	$114K	Hold	7,777	–	–	﹤0.01%	3175
2021 Q3	$233K	Hold	7,777	–	–	﹤0.01%	2501
2021 Q2	$361K	Hold	7,777	–	–	﹤0.01%	2222
2021 Q1	$467K	Buy	7,777 +2,687	+53%	+$183K	0.01%	1994
2020 Q4	$267K	Buy	5,090 +4,061	+395%	+$196K	﹤0.01%	2094
2020 Q3	$36K	Buy	+1,029	New	+$65.2K	﹤0.01%	2384
2020 Q1	–	Sell	-749	Closed	-$54K	–	2465
2019 Q4	$54K	Buy	+749	New	+$52.8K	﹤0.01%	2274
2019 Q2	–	Sell	-1,084	Closed	-$88K	–	2589
2019 Q1	$88K	Buy	+1,084	New	+$123K	﹤0.01%	2023

Other funds holding UBX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

ACM

Altium Capital Management New York $42M AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cubist Systematic Strategies's UBX Position: Q3 2022 in Review

Cubist Systematic Strategies sold out of Unity Biotechnology (UBX) in Q3 2022, closing a stake of 1,156 shares — an estimated $7K sold.

Cubist Systematic Strategies first reported a position in UBX in Q1 2019 and held it in 10 quarters. The position peaked at $467K in Q1 2021. 72 funds tracked by Wall St. Rank hold UBX as of Q3 2022.

Cubist Systematic Strategies reported no remaining Unity Biotechnology position as of Q3 2022 after selling out during the quarter.
Cubist Systematic Strategies sold 1,156 Unity Biotechnology shares in Q3 2022, an estimated $7K.
Cubist Systematic Strategies first reported a position in Unity Biotechnology in Q1 2019 and held it in 10 quarters.
Cubist Systematic Strategies's Unity Biotechnology position peaked at $467K in Q1 2021.
72 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2022.

Based on Cubist Systematic Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.